改良定义的高级腺瘤患者异时性进展期肿瘤风险:新罕布什尔结肠镜注册数据
基于新罕布什尔结肠镜注册数据,纳入35941名成人,比较10-19毫米管状腺瘤与改良高级腺瘤(含高级别异型增生、绒毛组织学或≥20毫米管状腺瘤)的异时性进展期肿瘤风险。结果显示改良高级腺瘤组异时性改良高级腺瘤风险显著高于10-19毫米管状腺瘤组(RR 1.52),结直肠癌风险数值更高但置信区间重叠。
要点
- 10-19毫米管状腺瘤与改良高级腺瘤的异时性进展期肿瘤风险置信区间重叠。
- 改良高级腺瘤组异时性改良高级腺瘤风险显著高于10-19毫米管状腺瘤组。
- 改良高级腺瘤组结直肠癌风险数值高于10-19毫米管状腺瘤组但无统计学差异。
核心结论
- 改良高级腺瘤组发生异时性改良高级腺瘤的风险显著高于10-19毫米管状腺瘤组(RR 1.52,95%CI 1.04-2.22)。
- 改良高级腺瘤组结直肠癌风险数值上高于10-19毫米管状腺瘤组,但置信区间重叠。
研究设计与样本
- 基于新罕布什尔结肠镜注册数据的回顾性队列研究,纳入35941名接受指数结肠镜并随访≥12个月的成人。
- 按指数发现分为5组:无腺瘤(n=20857)、1-2个小管状腺瘤(n=9927)、3-10个小管状腺瘤(n=2124)、10-19毫米管状腺瘤(n=1492)和改良高级腺瘤组(n=1541)。
- 使用泊松对数线性模型和Cox比例风险模型比较调整后异时性风险。
主要发现
- 与第1-3组相比,10-19毫米管状腺瘤组(RR 3.67,95%CI 2.99-4.50)和改良高级腺瘤组(RR 4.69,95%CI 3.82-5.77)的调整后异时性进展期肿瘤风险更高,置信区间重叠。
- 以改良高级腺瘤为结局,改良高级腺瘤组异时性改良高级腺瘤风险显著高于10-19毫米管状腺瘤组(RR 1.52,95%CI 1.04-2.22)。
- 与低风险组(第1-3组)相比,10-19毫米管状腺瘤组(HR 2.44,95%CI 1.34-4.44)和改良高级腺瘤组(HR 3.52,95%CI 1.98-6.25)的结直肠癌风险比更高,置信区间重叠。
关键数值与推荐
- 改良高级腺瘤定义包括高级别异型增生、绒毛组织学或管状腺瘤≥20毫米。
- 10-19毫米管状腺瘤组异时性进展期肿瘤率比(RR)为3.67(95%CI 2.99-4.50)。
- 改良高级腺瘤组异时性进展期肿瘤率比(RR)为4.69(95%CI 3.82-5.77)。
- 改良高级腺瘤组异时性改良高级腺瘤率比(RR)为1.52(95%CI 1.04-2.22)。
- 10-19毫米管状腺瘤组结直肠癌风险比(HR)为2.44(95%CI 1.34-4.44),改良高级腺瘤组为3.52(95%CI 1.98-6.25)。
临床怎么用
- 对于10-19毫米管状腺瘤患者,应认识到其异时性进展期肿瘤风险与改良高级腺瘤组有重叠。
- 改良高级腺瘤患者异时性改良高级腺瘤风险更高,可能需要更密切的随访。
- 改良高级腺瘤组结直肠癌风险数值更高,但需进一步研究验证。
局限性
- 研究为观察性注册数据,可能存在未测量混杂因素。
- 10-19毫米管状腺瘤组内异时性风险差异未进一步分析。
- 结论需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The term "advanced adenoma" (AA) includes adenomas ≥1 cm, ones with villous histology or high-grade dysplasia (HGD), or polyps that may be heterogeneous for metachronous advanced neoplasia (AN) risk (AA and adenocarcinoma). We compared risk in individuals with 10- to 19-mm tubular adenomas (TAs) vs those with HGD, villous histology, and TAs ≥20 mm (modified AAs). METHODS: We used the New Hampshire Colonoscopy Registry to identify individuals having index colonoscopies and follow-up exams 12 months or longer. Outcomes were metachronous AN and subsequent colorectal cancer (CRC). Using Poisson loglinear and Cox proportional hazards models, we compared adjusted metachronous risk of AA and CRC between the 2 AA subgroups and those with lesser findings. RESULTS: There were 35,941 adults stratified by index findings: Group 1: no adenomas (n = 20,857); Group 2: 1 to 2 small (<1 cm) TAs (n = 9927); Group 3: 3 to 10 small (<1 cm) TAs (n = 2124); Group 4: 10- to 19-mm TAs (n = 1492), and the modified AA group (Group 5) (n = 1541). Compared with Groups 1 to 3, Group 4 (rate ratio [RR], 3.67; 95% confidence interval [CI], 2.99-4.50) and Group 5 (RR, 4.69; 95% CI, 3.82-5.77) had higher adjusted AN risk, with overlapping 95% CIs. However, when using the modified AA definition as an outcome, we observed that the modified AA group had a statistically significantly higher risk for metachronous modified AA than the large (10-19 mm) TA group (RR, 1.52; 95% CI, 1.04-2.22). Compared with the low-risk groups (Groups 1-3), Group 4 (hazard ratio [HR], 2.44; 95% CI, 1.34-4.44) and Group 5 (HR, 3.52; 95% CI, 1.98-6.25) had higher HRs for CRC with overlapping CIs. CONCLUSIONS: The modified AA groups had a statistically higher risk of a modified AN outcome and a numerically higher CRC risk than the 10- to 19-mm TA group. Future studies should validate these findings and extend them by examining differences in metachronous risk within the 10- to 19-mm TA group.
引用
- Anderson JC, Mackenzie TA, Butterly LF, et al. Risk for Metachronous Advanced Neoplasia in Patients With a Modified Definition of Advanced Adenoma: Data From the New Hampshire Colonoscopy Registry. Clin Gastroenterol Hepatol. 2025. PMID: 40669579. doi:10.1016/j.cgh.2025.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。